...
首页> 外文期刊>Stem cells translational medicine. >Bone Marrow Endothelial Progenitor Cells Are the Cellular Mediators of Pulmonary Hypertension in the Murine Monocrotaline Injury Model
【24h】

Bone Marrow Endothelial Progenitor Cells Are the Cellular Mediators of Pulmonary Hypertension in the Murine Monocrotaline Injury Model

机译:骨髓内皮祖细胞是小鼠monocrotataline损伤模型中肺动脉高压的细胞介质。

获取原文
           

摘要

The role of bone marrow (BM) cells in modulating pulmonary hypertensive responses is not well understood. Determine if BM‐derived endothelial progenitor cells (EPCs) induce pulmonary hypertension (PH) and if this is attenuated by mesenchymal stem cell (MSC)‐derived extracellular vesicles (EVs). Three BM populations were studied: (a) BM from vehicle and monocrotaline (MCT)‐treated mice (PH induction), (b) BM from vehicle‐, MCT‐treated mice that received MSC‐EV infusion after vehicle, MCT treatment (PH reversal, in vivo), (c) BM from vehicle‐, MCT‐treated mice cultured with MSC‐EVs (PH reversal, in vitro). BM was separated into EPCs (sca‐1+/c‐kit+/VEGFR2+) and non‐EPCs (sca‐1‐/c‐kit‐/VEGFR2‐) and transplanted into healthy mice. Right ventricular (RV) hypertrophy was assessed by RV‐to‐left ventricle+septum (RV/LV+S) ratio and pulmonary vascular remodeling by blood vessel wall thickness‐to‐diameter (WT/D) ratio. EPCs but not non‐EPCs from mice with MCT‐induced PH (MCT‐PH) increased RV/LV+S, WT/D ratios in healthy mice (PH induction). EPCs from MCT‐PH mice treated with MSC‐EVs did not increase RV/LV+S, WT/D ratios in healthy mice (PH reversal, in vivo). Similarly, EPCs from MCT‐PH mice treated with MSC‐EVs pre‐transplantation did not increase RV/LV+S, WT/D ratios in healthy mice (PH reversal, in vitro). MSC‐EV infusion reversed increases in BM‐EPCs and increased lung tissue expression of EPC genes and their receptors/ligands in MCT‐PH mice. These findings suggest that the pulmonary hypertensive effects of BM are mediated by EPCs and those MSC‐EVs attenuate these effects. These findings provide new insights into the pathogenesis of PH and offer a potential target for development of novel PH therapies. S tem C ells T ranslational M edicine 2017;6:1595–1606
机译:骨髓(BM)细胞在调节肺动脉高压反应中的作用尚不清楚。确定BM来源的内皮祖细胞(EPC)是否诱发肺动脉高压(PH),以及是否由间充质干细胞(MSC)衍生的细胞外囊泡(EVs)减轻。研究了三个BM种群:(a)接受媒介物和单crocrotaline(MCT)处理的小鼠的BM(PH诱导),(b)接受媒介物,MCT处理的MSC-EV输注的接受MSC-EV的媒介物,MCT处理的小鼠的BM (c)用MSC-EVs培养的经媒介物,MCT处理的小鼠的BM(PH逆转,体外)。将BM分为EPC(sca-1 + / c-kit + / VEGFR2 +)和非EPC(sca-1 // ckit / VEGFR2)并移植到健康小鼠中。右室(RV)肥大通过RV与左心室+隔膜(RV / LV + S)的比率进行评估,并通过血管壁厚与直径(WT / D)的比率进行肺血管重构。具有MCT诱导的PH(MCT-PH)的小鼠的EPC但非EPC却增加了健康小鼠的RV / LV + S,WT / D比(PH诱导)。用MSC-EVs处理的MCT-PH小鼠的EPC并未增加健康小鼠的RV / LV + S,WT / D比率(体内PH逆转)。同样,在移植前,用MSC-EVs处理过的MCT-PH小鼠的EPC不会增加健康小鼠的RV / LV + S,WT / D比(PH逆转,体外)。 MSC-EV输注逆转了MCT-PH小鼠中BM-EPC的增加,并增加了肺组织EPC基因及其受体/配体的表达。这些发现表明BM的肺动脉高压作用是由EPC介导的,而MSC-EV则减弱了这些作用。这些发现为PH的发病机理提供了新的见解,并为开发新型PH疗法提供了潜在的靶标。系统杂志翻译医学杂志,2017年; 6:1595-1606

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号